TY - JOUR
T1 - Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study.
AU - Valerio, Maria Rosaria
AU - Colangelo, null
AU - De Vincenzo, null
AU - Lorusso, null
AU - Colangelo, null
AU - Scambia, null
AU - Prantera, Tullia
AU - Salutari, Vanda
AU - Ferrandina, Gabriella
AU - Lorusso, Domenica
AU - Scambia, Giovanni
AU - Ludovisi, null
PY - 2007
Y1 - 2007
N2 - A prospective phase II study was conducted to evaluate the efficacyand toxicity of the combination docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) in ovarian cancer patients recurring after a platinum-free interval (PFI) >12months. PATIENTS AND METHODS: DTX, 75 mg/m(2), was administered by 60 min i.v.infusion, followed by OXA, 100 mg/m(2), given by a 2 h i.v., on day 1 every 21days. RESULTS: From October 2003 to June 2006, 43 ovarian cancer patients wereenrolled. Median PFI was 26 months. All patients were available for responseevaluation: 17 complete responses and 12 partial responses were registered, foran overall response rate of 67.4%. The median response duration was 10 months.Stable disease was documented in 11 patients (median duration = 5.5 months). The median time to progression and overall survival were 14 and 28 months. A total of259 courses were administered. Grade 3-4 leukopenia was documented in 32.5% ofthe patients, while no case of severe anemia and thrombocytopenia was observed.Grade 3-4 neurotoxicity and grade 2 alopecia were observed in 9.3% and 34.9% ofcases, respectively. CONCLUSION: DTX/OXA combination is an active regimen with a favorable toxicity profile, for treatment of recurrent platinum-sensitive ovarian
AB - A prospective phase II study was conducted to evaluate the efficacyand toxicity of the combination docetaxel (Taxotere) (DTX) and oxaliplatin (OXA) in ovarian cancer patients recurring after a platinum-free interval (PFI) >12months. PATIENTS AND METHODS: DTX, 75 mg/m(2), was administered by 60 min i.v.infusion, followed by OXA, 100 mg/m(2), given by a 2 h i.v., on day 1 every 21days. RESULTS: From October 2003 to June 2006, 43 ovarian cancer patients wereenrolled. Median PFI was 26 months. All patients were available for responseevaluation: 17 complete responses and 12 partial responses were registered, foran overall response rate of 67.4%. The median response duration was 10 months.Stable disease was documented in 11 patients (median duration = 5.5 months). The median time to progression and overall survival were 14 and 28 months. A total of259 courses were administered. Grade 3-4 leukopenia was documented in 32.5% ofthe patients, while no case of severe anemia and thrombocytopenia was observed.Grade 3-4 neurotoxicity and grade 2 alopecia were observed in 9.3% and 34.9% ofcases, respectively. CONCLUSION: DTX/OXA combination is an active regimen with a favorable toxicity profile, for treatment of recurrent platinum-sensitive ovarian
UR - http://hdl.handle.net/10447/47513
M3 - Article
VL - 18
SP - 1348
EP - 1353
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
ER -